Blood Thinners & Atherosclerosis: How Anticoagulants Reduce Risk

Role of Antithrombotic Therapy in Atherosclerosis

Atherosclerosis narrows arteries with plaque. Rupture exposes thrombogenic core → platelet adhesion → thrombus → acute coronary syndrome (ACS) or stroke. Antithrombotics target this cascade.

Antiplatelets (First-Line for Arterial Disease)

  • Aspirin (75–100 mg): Irreversible COX-1 inhibition → ↓TXA₂. Primary prevention: selective (ASCVD risk >10%/10yr, age 40–70). Secondary prevention: indefinite post-MI/stent/PAD/stroke.
  • P2Y₁₂ Inhibitors (Clopidogrel, Ticagrelor, Prasugrel): ADP receptor blockade. Dual antiplatelet therapy (DAPT) post-ACS/stent (6–12 mo).

Anticoagulants (For Atrial Fibrillation, VTE, Mechanical Valves)

  • DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — preferred over warfarin for non-valvular AF.
  • Not routine for stable atherosclerosis alone.

Mechanisms of Benefit

  1. Prevent Thrombus on Ruptured Plaque: ↓MI, stroke.
  2. Improve Microcirculation: ↓blood viscosity → ↑perfusion.
  3. Anti-Inflammatory (Aspirin): ↓CRP, ↓plaque progression (modest).
  4. Plaque Stabilization: Some evidence for statin+aspirin synergy.

Risks

  • Bleeding (GI, intracranial) — risk ↑ with age, H. pylori, NSAIDs, steroids, anticoagulant combo.
  • Assess HAS-BLED (anticoagulants) or aspirin-specific scores.

Not a Substitute for Risk Factor Control

Statins, BP control, diabetes management, smoking cessation, exercise, Mediterranean diet remain foundational. Antithrombotics treat thrombotic complications, not the plaque itself.

Blood Disorders - Related Articles